Sanofi India Gets GST Refund Order of ₹52 Lakhs, Appeals for ₹11.6 Lakhs
Sanofi India received a GST refund order of ₹52.08 Lakhs, comprising ₹33.97 Lakhs principal and ₹18.11 Lakhs interest, for the period August 2014 to June 2017. The company will appeal for the un-granted ₹11.63 Lakhs of its ₹45.60 Lakhs claim.
The amount involved in the refund dispute is relatively small compared to the company's overall financial standing, hence the impact is considered low.
While the company received a partial refund, a portion of the claim was rejected, and the company plans to appeal. The outcome is not definitively positive or negative.
Sanofi India Limited has received an order from the Assistant Commissioner - Central Goods & Service Tax, Division -VIII, Ankleshwar, Vadodara, concerning a refund claim for periods between August 2014 and June 2017.
The company was granted a partial refund of ₹52,07,841, which includes a principal refund of ₹33,96,705 and interest of ₹18,11,136. This order was received by the company on 21st April 2026.
However, the Assistant Commissioner did not accept the full refund claim, leaving ₹11,62,853 of the claimed amount un-granted. The company had initially filed a refund application of ₹45,59,558, representing a pre-deposit payment made during an appeal process, as the matter was decided in their favor. Sanofi India Limited intends to file an appeal before the Appellate authorities for the non-grant of the balance refund of ₹11,62,853.
What to do with a filing like this
Sanofi India Limited filed this with the NSE as a statutory disclosure, categorised under regulatory impact. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sanofi India Limited. Read the original for the full detail.